Abstract
Hepatocellular carcinoma (HCC) is a major cause of cancer death worldwide. As in many other types of cancer, aberrant activation of the canonical Wnt/β-catenin signaling pathway is an important contributor to tumorigenesis. In HCC this frequently occurs through mutations in the N-terminal region of β-catenin that stabilize the protein and permit an elevated level of constitutive transcriptional activation by β-catenin/TCF complexes. In this article we review the abundant evidence that Wnt/β-catenin signaling contributes to liver carcinogenesis. We also discuss what is known about the roles of Wnt signaling in liver development, regeneration, and stem cell behavior, in an effort to understand the mechanisms by which activation of the canonical Wnt pathway promotes tumor formation in this organ. The Wnt/β- catenin pathway presents itself as an attractive target for developing novel rational therapies for HCC, a disease for which few successful treatment strategies are currently available.
Keywords: Liver Cancer, Wnt Signaling, Hepatocellular carcinoma (HCC), tumorigenesis, β-catenin/TCF complexes, stem cell
Current Drug Targets
Title: Wnt Signaling in Liver Cancer
Volume: 9 Issue: 11
Author(s): Yutaka Takigawa and Anthony M.C. Brown
Affiliation:
Keywords: Liver Cancer, Wnt Signaling, Hepatocellular carcinoma (HCC), tumorigenesis, β-catenin/TCF complexes, stem cell
Abstract: Hepatocellular carcinoma (HCC) is a major cause of cancer death worldwide. As in many other types of cancer, aberrant activation of the canonical Wnt/β-catenin signaling pathway is an important contributor to tumorigenesis. In HCC this frequently occurs through mutations in the N-terminal region of β-catenin that stabilize the protein and permit an elevated level of constitutive transcriptional activation by β-catenin/TCF complexes. In this article we review the abundant evidence that Wnt/β-catenin signaling contributes to liver carcinogenesis. We also discuss what is known about the roles of Wnt signaling in liver development, regeneration, and stem cell behavior, in an effort to understand the mechanisms by which activation of the canonical Wnt pathway promotes tumor formation in this organ. The Wnt/β- catenin pathway presents itself as an attractive target for developing novel rational therapies for HCC, a disease for which few successful treatment strategies are currently available.
Export Options
About this article
Cite this article as:
Takigawa Yutaka and Brown M.C. Anthony, Wnt Signaling in Liver Cancer, Current Drug Targets 2008; 9 (11) . https://dx.doi.org/10.2174/138945008786786127
DOI https://dx.doi.org/10.2174/138945008786786127 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
From Amino Acids to Proteins as Targets for Metal-based Drugs
Current Drug Metabolism Therapeutic Potential of Peptide Toxins that Target Ion Channels
Inflammation & Allergy - Drug Targets (Discontinued) Combined Treatment with PPAR-γ Agonists in Pancreatic Cancer: A Glimmer of Hope for Cancer Therapy?
Current Cancer Drug Targets Pharmacological Activation of p53 in Cancer Cells
Current Pharmaceutical Design Carbon Nanotubes: Classification, Method of Preparation and Pharmaceutical Application
Current Drug Delivery Dual Topoisomerase I / II Inhibitors in Cancer Therapy
Current Topics in Medicinal Chemistry Ferroptosis: A Novel Mechanism of Artemisinin and its Derivatives in Cancer Therapy
Current Medicinal Chemistry Dietary Polyphenols for Prostate Cancer Therapy
Current Bioactive Compounds Advances in Recombinant Adeno-Associated Viral Vectors for Gene Delivery
Current Gene Therapy BMPS and Liver: More Questions than Answers
Current Pharmaceutical Design Clinical Applications and Biosafety of Human Adult Mesenchymal Stem Cells
Current Pharmaceutical Design Volatilome Metabolomics and Databases, Recent Advances and Needs
Current Metabolomics Self-Assembled Peptide Nanoarchitectures: Applications and Future Aspects
Current Topics in Medicinal Chemistry Epigenetic and Disease Targets by Polyphenols
Current Pharmaceutical Design Bcl-2 Inhibitors: Emerging Drugs in Cancer Therapy
Current Medicinal Chemistry Anti-CD20 Antibody in Primary Sjogren's Syndrome Managemen
Current Pharmaceutical Biotechnology New Purine Nucleoside Analogs for Acute Lymphoblastic Leukemia
Clinical Cancer Drugs PSMA7, A Potential Biomarker of Diseases
Protein & Peptide Letters Cell Cycle and Energy Metabolism in Tumor Cells: Strategies for Drug Therapy
Recent Patents on Anti-Cancer Drug Discovery CDC25A and B Dual-Specificity Phosphatase Inhibitors: Potential Agents for Cancer Therapy
Current Medicinal Chemistry